A new sustained release dosage form of valproic acid (VPA) was developed. The new sustained release dosage form was administered (twice, with and without food) to five dogs in comparison to a standard tablet (Depakine, Labaz) and an i.v. preparation of the drug. Drug level monitoring in the plasma w
Pharmacokinetic evaluation of novel sustained-release dosage forms of valproic acid in humans
โ Scribed by Meir Bialer; Michael Friedman; Joseph Dubrovsky; Itamar Raz; Oded Abramsky
- Publisher
- John Wiley and Sons
- Year
- 1985
- Tongue
- English
- Weight
- 444 KB
- Volume
- 6
- Category
- Article
- ISSN
- 0142-2782
No coin nor oath required. For personal study only.
โฆ Synopsis
- Five new sustained-release dosage forms of valproic acid (VPA) were developed. 2. The new sustained-release formulations were administered to six healthy subjects for comparison with a standard tablet and an i.v. preparation of the drug. 3. Three of the formulations exhibited a more prolonged and uniform absorption rate and yielded more sustained serum levels after ingestion. These three formulations maintained serum therapeutic levels of VPA for 24 h after a single oral administration of 1 g, and were bioequivalent to a marketed standard tablet of VPA. 4. The absorption profile of the various oral formulations was analysed pharmacokinetically, using the Loo-Riegelman procedure.
๐ SIMILAR VOLUMES
A pharmacokinetic analysis of two sustained-release dosage forms of theophylline (Theo-Dur@ and Theotrim@) was carried out following single and multiple dose administrations of the two formulations in five healthy subjects. Despite the prolonged absorption after administration of the two sustained-r
Novel drug reservoirs are described which, after their implantation under mouse skin, continuously released organic liquids such as the anti-epileptic drug valproic acid at preselected rates for periods up to several weeks. The liquids, which were filled into the reservoirs, diffused through silasti